November 8, 2017 07:35 PM ESTUpdated 06:17 AM

Eyeing Duchenne MD cure, The Column Group gambles $40M on CRISPR/Cas9 startup Exonics

Amber Tong

The Column Group thinks that gene editing may provide just the right kind of technology needed to cure Duchenne muscular dystrophy. And the investment group …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Eyeing Duchenne MD cure, The Column Group gambles $40M on CRISPR/Cas9 startup Exonics

Amber Tong

Sign up to read this article for free.

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Bristol Myers reveals more job cuts in New Jersey

Merck halts Phase 3 trial with PAH drug Winrevair following positive interim data

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

AstraZeneca’s Truqap edges closer to prostate cancer label expansion with Phase 3 win

Eye­ing Duchenne MD cure, The Col­umn Group gam­bles $40M on CRISPR/Cas9 start­up Ex­on­ics

Amber Tong

Sign up to read this article for free.

more like this

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Bris­tol My­ers re­veals more job cuts in New Jer­sey

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

As­traZeneca’s Truqap edges clos­er to prostate can­cer la­bel ex­pan­sion with Phase 3 win

Eyeing Duchenne MD cure, The Column Group gambles $40M on CRISPR/Cas9 startup Exonics

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Bristol Myers reveals more job cuts in New Jersey

Merck halts Phase 3 trial with PAH drug Winrevair following positive interim data

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

AstraZeneca’s Truqap edges closer to prostate cancer label expansion with Phase 3 win